Table 2.

Clinical characteristics of participants in a crossover trial assessing the dialyzability of four β-blockers

Subject IdentificationBB002BB003BB004BB005BB006BB007BB008BB009
SexManManManWomanManManManMan
EthnicityWhiteWhiteWhiteWhiteAboriginalBlack CanadianWhiteWhite
Age, yr4273662847728053
Weight, kg9412954821189090106
Height, m1.71.91.71.51.71.61.71.8
Body mass index, kg/m232.235.619.237.738.733.830.333.6
Residual kidney output, ml/d300425260AnuricAnuric500300300
Cause of CKDRPGNDM and HTNPCKDRenux nephropathDM and HTNHTNDM and HTNDM
Dialysis duration, h4433.54434
Dialysis frequency, sessions per week33333333
Dialyzer typeFX800FX1000FX600FX600FX1000FX800FX600Revaclear Max 400
Mean blood flow rate, ml/mina382323354397287385325313
Dialysis adequacy, Kt/Va1.5±0.041.1±0.121.4±0.111.6±0.151.2±0.021.6±0.031.0±0.041.1±0.03
Vascular accessCentral catheterCentral catheterFistulaFistulaCentral catheterCentral catheterFistulaFistula
Hematocrit, predialysisa0.27±0.010.30±0.010.33±0.010.29±0.010.27±0.010.28±0.010.29±0.020.35±0.01
Hematocrit, postdialysisa0.24±0.010.34±0.020.36±0.010.33±0.010.28±0.010.30±0.010.32±0.030.37±0.01
  • RPGN, rapidly progressive GN; DM, diabetes mellitus; HTN, hypertension; PCKD, polycystic kidney disease.

  • a Mean over the four dialysis sessions ±SD.